General Information of the Compound
| Compound ID |
CP0013326
|
||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Compound Name |
BARICITINIB
Show/Hide
|
||||||||||||||||||
| Synonyms |
Baricitinib
Baricitinib (LY3009104, INCB028050)
Baricitinib [USAN:INN]
C16H17N7O2S
INCB 028050
INCB-028050
INCB028050
ISP4442I3Y
J-503551
LY-3009104
LY3009104
Olumiant (TN)
UNII-ISP4442I3Y
olumiant
Show/Hide
|
||||||||||||||||||
| Structure |
|
||||||||||||||||||
| Formula |
C16H17N7O2S
|
||||||||||||||||||
| Molecular Weight |
371.426
|
||||||||||||||||||
| Canonical SMILES |
CCS(=O)(=O)N1CC(CC#N)(C1)n1cc(cn1)-c1ncnc2[nH]ccc12
Show/Hide
|
||||||||||||||||||
| InChI |
InChI=1S/C16H17N7O2S/c1-2-26(24,25)22-9-16(10-22,4-5-17)23-8-12(7-21-23)14-13-3-6-18-15(13)20-11-19-14/h3,6-8,11H,2,4,9-10H2,1H3,(H,18,19,20)
Show/Hide
|
||||||||||||||||||
| InChIKey |
XUZMWHLSFXCVMG-UHFFFAOYSA-N
|
||||||||||||||||||
| CAS |
1187594-09-7
|
||||||||||||||||||
| Physicochemical Property |
"RO5" indicates the cutoff set by lipinski's rule of five: (1) Molecular weight less than 500 Dalton; (2) xlogp less than 5; (3) No more than 5 hbonddonor (Hydrogen Bond Donor Count); (4) No more than 10 hbondacc (Hydrogen Bond Acceptor Count); (5) No more than 10 rotbonds (Rotatable Bond Count). Show/Hide
|
||||||||||||||||||
| Click to Show/Hide the External Link(s) of This Compound | |||||||||||||||||||
| PubChem ID | |||||||||||||||||||
| ChEMBL ID | |||||||||||||||||||
| DrugBank ID | |||||||||||||||||||
Map of Molecular Bioactivity Related to the Compound
|
Map of Molecular Bioactivity Related to the Compound Compound Cell Line Protein Bioactivity Value: <= 0.1 μM > 0.1 μM and <= 10 μM > 10 μM Imprecise Activity |
|
|---|
Table of Molecular Bioactivities Related to the Compound
Clinical Information about the Compound
Drug 1 ( Baricitinib )
| Drug Name | Baricitinib | ||
|---|---|---|---|
| Company | Incyte/Eli Lilly | ||
| Indication | |||
| Target(s) | |||